Global microbial gene editing services demand is anticipated to be valued at USD 5.35 Billion in 2022, forecast to grow at a CAGR of 19% to be valued at USD 30.5 Billion from 2022 to 2032.
Microbial gene editing is a technology that has the ability to change the DNA of organisms. Microbial gene editing is changing the ways of developing new medical treatments. From treating diseases such as sickle cell and HIV to custom pets and designer babies, microbial gene editing has great potential to affect all areas of life in the near future.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | USD 4.5 Billion |
| Expected Market Value (2022) | USD 5.35 Billion |
| Anticipated Forecast Value (2032) | USD 30.5 Billion |
| Projected Growth Rate (2022 to 2032) | 19% CAGR |
Development of new immunotherapies for diseases such as cancer as the rising prevalence of cancer which will significantly grow in the future will provide an opportunity for microbial gene editing. For instance, the first-ever human trials of CRISPR focused on treating various cancers in China and the first human trials for CRISPR tech in the USA set to focus on diseases such as sickle cell.
Progress in the availability of computational tools and wet-lab genome editing (GE) technologies has greatly expanded the capability for the complex requirements of a system-level investigation of microbes.
Microbial gene editing tools such as targeting, zinc finger nucleases (ZFNs), meganucleases (MillioNs), (CRISPR)-associated nuclease Cas9 and transcription activator-like effector nucleases (TALENs), and, creates huge opportunity for the gene editing in the forecast period. All these tools can achieve accurate and precise genetic modifications by inducing targeted DNA double-strand breaks.
Explore FMI!
Book a free demo
Recent research and development in genome editing technologies hold promise in the forecast period for the development of innovative therapies. The use of genome tools has the potential to affect various therapeutic areas and hundreds of diseases, common and rare diseases which will significantly boost the market.
Over the years, Increased attention is given to the development of new antimicrobials which fight against antibiotic-resistant bacteria. For instance, Companies such as Nemesis Bioscience and Eligo Bioscience are developing antimicrobial technology and treatments with the help of CRISPR technology. Increasing government funding and the development of fast and easy methods with high efficiency spur the microbial gene editing services market in the forecast period.
Other factors like rising acceptance and increasing medical research and development for gene editing, growth of established and new gene editing tools, and rising clinical trials for diseases as diverse as muscular dystrophy, cancer, and sickle cell anemia will further drive the microbial gene editing services market. In addition to these factors, an increasing number of skilled laborers will create opportunities for the development of new tools in the future which will bring significant growth in the revenue of the microbial gene editing services market in the forecast period.
The challenges associated with the growth of the global microbial gene editing services market are variations in regulatory standards for different regions or countries. Moreover, certain limitations to the available tool and high costs associated with the editing systems might restrain the growth of the microbial gene editing services market.
According to Future Market Insights, the North American market for Microbial Gene Editing Services holds the largest revenue share, due to increasing research and development and rising government funding for microbial gene editing research.
For instance, in 2018, The USA National Institutes of Health (NIH) announced to grant USD190 million for genome editing research. The launch of genome editing programs by NIH such as Somatic Cell Genome Editing programs which aims to develop tools for safe and effective genome editing in humans spur the market of North America in the forecast period.
As per the FMI analysis, Europe accounts for the second largest revenue share in the global microbial gene editing services market, owing to the increasing prevalence of diseases such as HIV and Cancer and the development of new innovative technology and new drugs along with the increasing number of skilled laborers. Moreover, rapid growth is expected in the microbial gene editing services market, due to advances in technology and the establishment of scientific research groups and laboratories.
Asia Pacific is expected to witness rapid growth in the microbial gene editing services market, due to increasing awareness of gene editing services in developing countries such as India and improving healthcare infrastructure. China is expected to register significant growth in the microbial gene editing services market, due to favorable regulations and advancements in biotechnology.
Some of the key participants present in the global microbial gene editing services market include Creative Biogene, GeneCopoeia, Inc., ProteoGenix, Thermo Fisher Scientific Inc., Vigene Biosciences Inc, Biotools Co.Ltd, Cellecta, In, NemaMetrix Inc, GenScript Biotech Corp, OriGene Technologies, Inc, Synbio Technologies LLC, ABM Inc, and Rockland Immunochemicals Inc., among others. Attributed to the presence of such a high number of participants, the market is highly competitive.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | USD 5.35 Billion |
| Market Value in 2032 | USD 30.5 Billion |
| Growth Rate | CAGR of 19% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Tools, Application, End User, Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia and the Pacific; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, Italy, France, Spain, United Kingdom, BENELUX, Russia, China, Japan, South Korea, India, ASIAN, Australia & New Zealand, GCC Countries, Turkey, South Africa |
| Key Companies Profiled | Creative Biogene; GeneCopoeia, Inc.; ProteoGenix; Thermo Fisher Scientific Inc.; Vigene Biosciences Inc.; Biotools Co. Ltd; Cellecta Inc.; InVivo Biosystems; GenScript Biotech Corp.; OriGene Technologies Inc.; Synbio Technologies LLC; Abm Inc.; Rockland Immunochemicals Inc. |
| Customization | Available Upon Request |
FMI projects the global microbial gene editing services market to expand at a 19% value CAGR by 2032
North America is expected to be the most opportunistic microbial gene editing services market.
Creative Biogene, GeneCopoeia, Inc., and ProteoGenix, are some prominent microbial gene editing services manufacturers.
Acrylic Teeth Market Trends and Assessment for 2025 to 2035
Bariatric Beds Market Analysis and Forecast for 2025 to 2035
Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market Growth and Analysis: 2025 to 2035
Uterine Manipulation Devices Market - Growth & Demand 2025 to 2035
Retinal Vein Occlusion Treatment Market - Outlook 2025 to 2035
Klinefelter Syndrome Therapeutics Market - Growth & Demand 2025 to 2035
Microbial Gene Editing Services Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
